• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: SIEMENS HEALTHCARE DIAGNOSTICS, INC. ADVIA CENTAUR XP ANTI-HBS2 (AHBS2); AHBS2 IMMUNOASSAY

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

SIEMENS HEALTHCARE DIAGNOSTICS, INC. ADVIA CENTAUR XP ANTI-HBS2 (AHBS2); AHBS2 IMMUNOASSAY Back to Search Results
Model Number N/A
Device Problem No Apparent Adverse Event (3189)
Patient Problem No Known Impact Or Consequence To Patient (2692)
Event Date 11/18/2019
Event Type  malfunction  
Manufacturer Narrative
Siemens is investigating.
 
Event Description
A customer obtained discordant positive advia centaur xpt anti-hbs2 (ahbs2) patient results compared to the clinical picture, other clinical diagnostic test results as well as to the atellica im ahbs2 assay.There are no reports that treatment was altered or prescribed or adverse health consequences due to the discordant advia centaur xpt ahbs2 results.
 
Manufacturer Narrative
Siemens filed mdr 1219913-2019-00270 reporting discordant positive advia centaur xpt anti-hbs2 (ahbs2) patient results (initial and repeat testing from one sample) compared to the clinical picture, other clinical diagnostic test results as well as to the atellica im ahbs2 assay.Additional information - january 3, 2020.Based on the information received, no product problem has been identified.Siemens cannot rule out preanalytical factors or a sample issue or normal assay performance for the false positive results seen by the customer.Siemens reviewed the calibration and control data provided and there is no evidence of a problem.The patient has hbv but the customer was not able to provide a list of medications/supplements the patient is taking.There is no sample that can be sent to siemens for evaluation.The clinical sensitivity and specificity section of the advia centaur xp/xpt anti-hbs2.Instructions for use (ifu) lists the 95% confidence interval (ci) for resolved relative specificity as 98.34% - 99.88% so a certain number of false positive results can be expected for this assay.This 1 false positive sample does not indicate a product problem with advia centaur xpt ahbs2 lot 116.The cause of the false positive results seen by the customer with this one sample when using advia centaur xpt ahbs2 lot 116 could not be determined but siemens cannot rule out pre-analytical factors, a sample issue, or normal assay performance.Based on the investigation, no product problem was identified.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ADVIA CENTAUR XP ANTI-HBS2 (AHBS2)
Type of Device
AHBS2 IMMUNOASSAY
Manufacturer (Section D)
SIEMENS HEALTHCARE DIAGNOSTICS, INC.
511 benedict avenue
tarrytown NY 10591 5097
MDR Report Key9472722
MDR Text Key219589567
Report Number1219913-2019-00270
Device Sequence Number1
Product Code LOM
UDI-Device Identifier00630414561790
UDI-Public00630414561790
Combination Product (y/n)N
PMA/PMN Number
P100039
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional,u
Type of Report Initial,Followup
Report Date 01/27/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date09/28/2020
Device Model NumberN/A
Device Catalogue Number10286268
Device Lot Number64087116
Was Device Available for Evaluation? No
Initial Date Manufacturer Received 12/03/2019
Initial Date FDA Received12/16/2019
Supplement Dates Manufacturer Received01/03/2020
Supplement Dates FDA Received01/27/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
-
-